Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...

Descripción completa

Detalles Bibliográficos
Autores principales: Burack, Michelle, Aldred, Jason, Zadikoff, Cindy, Vanagunas, Arvydas, Klos, Kevin, Bilir, Bahri, Fernandez, Hubert H., Standaert, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://www.ncbi.nlm.nih.gov/pubmed/30363427
http://dx.doi.org/10.1002/mdc3.12630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://www.ncbi.nlm.nih.gov/pubmed/30363427
http://dx.doi.org/10.1002/mdc3.12630

Ejemplares similares